Cargando…

Real-World Early Treatment with Room Temperature–Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc Analyses

Treating hemophilia A or B patients with inhibitors is particularly challenging, as they do not respond to replacement therapy with factor VIII or factor IX concentrates. A room temperature–stable formulation of recombinant activated factor VII (rFVIIa; NovoSeven (®) ), which provides improved conve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Demartis, Francesco, Batorova, Angelika, Chambost, Hervé, Eshghi, Peyman, Karimi, Mehran, Kavakli, Kaan, El Fegoun, Soraya Benchikh, Cepo, Katarina, Vestergaard, Lene Sommer, Benson, Gary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2017
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524848/ https://www.ncbi.nlm.nih.gov/pubmed/31249918 http://dx.doi.org/10.1055/s-0037-1608943

Ejemplares similares

HAEMOcare: The First International Epidemiological Study Measuring Burden of Hemophilia in Developing Countries
por: Gupta, Naresh, et al.
Publicado: (2019)

Prospective Evaluation of Non-Compliant Severe Hemophilia Patients
por: Uğur, Mehmet Can, et al.
Publicado: (2019)

Limited factor VIIa surface localization requirement of the factor VIIa–induced overall thrombin generation in platelet‐rich hemophilia A plasma
por: Persson, Egon, et al.
Publicado: (2019)

Extended Half-Life Coagulation Factors: A New Era in the Management of Hemophilia Patients
por: Ar, Muhlis Cem, et al.
Publicado: (2019)

A novel supplemental approach to capturing post-marketing safety information on recombinant factor VIIa in acquired hemophilia: the Acquired Hemophilia Surveillance project
por: Lentz, Steven R, et al.
Publicado: (2014)

A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand
por: Mehta, Darshan A., et al.
Publicado: (2016)

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
por: Shapiro, Amy D., et al.
Publicado: (2022)

Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients
por: Abolghasemi, Hassan, et al.
Publicado: (2018)

Violin concertos in C major, Hob. VIIa:1 ; in G major, Hob. VIIa:4 ; in A major, Hob. VIIa:3 /
por: Haydn, Joseph, 1732-1809
Publicado: (1989)

Predictive Modeling Identifies Total Bleeds at 12-Weeks Postswitch to N8-GP Prophylaxis as a Predictor of Treatment Response
por: Chowdary, Pratima, et al.
Publicado: (2021)

Double J stent reduces the efficacy of extracorporeal shock wave lithotripsy in the treatment of lumbar ureteral stones
por: Pettenati, Caroline, et al.
Publicado: (2013)

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B
por: Shapiro, Amy D., et al.
Publicado: (2023)

Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa
por: Butros, Linda, et al.
Publicado: (2011)

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa
por: Lentz, S R, et al.
Publicado: (2014)

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
por: Mahlangu, Johnny, et al.
Publicado: (2021)

Iranian Low-dose Escalating Prophylaxis Regimen in Children with Severe Hemophilia A and B
por: Eshghi, Peyman, et al.
Publicado: (2017)

A Cross-National Survey of People Living with Hemophilia: Impact on Daily Living and Patient Education in Central Europe
por: Banchev, Atanas, et al.
Publicado: (2021)

Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A
por: Batorova, Angelika, et al.
Publicado: (2022)

Haemophilia in the developing countries: the Iranian experience
por: Eshghi, Peyman, et al.
Publicado: (2010)

A Polymorphism in the IL-5 Gene is Associated with Inhibitor Development in Severe Hemophilia A Patients
por: Fidancı, İnanç Değer, et al.
Publicado: (2014)

First experience of a hemophilia monitoring platform: florio HAEMO
por: Zapotocka, Ester, et al.
Publicado: (2022)

Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)
por: Zollner, S, et al.
Publicado: (2014)

P1620: A CROSS-NATIONAL SURVEY OF PEOPLE LIVING WITH HEMOPHILIA: REPORTED PAIN, IMPACT ON PHYSICAL ACTIVITY AND OPPORTUNITY ON USING DIGITAL TOOLS FOR MONITORING HAEMOPHILIA
por: Banchev, Atanas, et al.
Publicado: (2023)

Factor VIIa for severe cardiac surgical bleeding
por: Diprose, P, et al.
Publicado: (2002)

Preclinical trauma studies of recombinant factor VIIa
por: Schreiber, Martin A, et al.
Publicado: (2005)

Evaluation of Knowledge of Patients with Hemophilia Regarding Their Diseases and Treatment in Iran
por: Karimi, Mehran, et al.
Publicado: (2016)

Use of a High-Purity Factor X Concentrate in Turkish Subjects with Hereditary Factor X Deficiency: Post Hoc Cohort Subanalysis of a Phase 3 Study
por: Öner, Ahmet F., et al.
Publicado: (2018)

The impact of inhibitors on the quality of life in patients with hemophilia
por: Haghpanah, Sezaneh, et al.
Publicado: (2023)

Use of recombinant factor VIIa in orthotopic liver transplant
por: Bhatia, Pradeep
Publicado: (2011)

A case of bilateral tibial hemimelia type VIIa
por: Chinnakkannan, Selvakumar, et al.
Publicado: (2013)

The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors
por: Meeks, Shannon L., et al.
Publicado: (2019)

Hemoaction Game: An educational Step to Improve Hemophilia Children and Nurses Self-Efficacy
por: BEHESHTIPOOR, NOOASHIN, et al.
Publicado: (2016)

A comparison between on-demand usage of rFVIIa vs prophylaxis use of emicizumab in high titer inhibitory hemophilia A patients in Iran: A cost–utility analysis
por: Saiyarsarai, Parisa, et al.
Publicado: (2021)

Termination of pregnancy due to Thalassemia major, Hemophilia, and Down's Syndrome: the views of Iranian physicians
por: Karimi, Mehran, et al.
Publicado: (2008)

Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage
por: Kissela, Brett M, et al.
Publicado: (2008)

Recombinant factor VIIa in severe trauma: further study needed
por: Galvan, Dan A, et al.
Publicado: (2006)

Recombinant Activated Factor VIIa Treatment for Refractory Hemorrhage in Infants
por: Dang, Chi N, et al.
Publicado: (2010)

Recombinant Factor VIIa: Hemostatic Adjunct in the Coagulopathic Burn Patient
por: Martin, Jeremiah T., et al.
Publicado: (2009)

The utility of recombinant factor VIIa as a last resort in trauma
por: Mamtani, Rishi, et al.
Publicado: (2012)

Recombinant factor VIIa use in patients presenting with intracranial hemorrhage
por: Yampolsky, Natalie, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_o2vrppv23o5jt8qo90fd1ign5s